Brazil · Delayed Price · Currency is BRL Dimed S.A. Distribuidora de Medicamentos Earnings Call Transcripts
Fiscal Year 2025
-
Sales grew 17% in 2025, with digital and own-brand products driving revenue and margin gains. EBITDA margin reached 5.4%, and net income rose 35% year-over-year. Outlook remains strong with expansion in generics, digital, and store footprint, targeting BRL 12 billion revenue by 2030.
-
Q3 2025 saw strong sales growth of 14.3%, robust digital expansion, and a 32.6% rise in private label sales. EBITDA and cash flow improved, while net income was impacted by higher interest rates. The outlook remains positive, with continued focus on digital, private label, and generics.
-
Q2 2025 saw nearly 20% sales growth, strong EBITDA and net income gains, and continued market share expansion, driven by digital, private label, and store expansion strategies. Positive trends are expected to continue, with further margin improvements and growth in key categories.
-
Q1 2025 saw 15.9% sales growth, stable 29.4% retail gross margin, and 7% EBITDA growth, driven by mature store productivity, digital expansion, and private label gains. Market share increased for the 20th consecutive quarter, with strong cash flow and low leverage.
Fiscal Year 2024
-
Q4 and full-year 2024 saw strong sales and EBITDA growth, despite major flood disruptions in Q2. Retail revenues topped BRL 5 billion, digital sales surged, and market share expanded, with a positive outlook for 2025 driven by new store openings, product launches, and digital innovation.
-
Q3 2024 saw robust 17% revenue growth, margin expansion, and strong digital sales, rebounding from Q2 flood impacts. Market share increased across southern Brazil, with continued store expansion and disciplined capital management. Leverage remains low, and outlook for Q4 and 2025 is positive.
-
Q2 2024 saw 11.5% sales growth and strong digital gains despite severe flooding, with all direct flood impacts fully recognized and a positive free cash flow. Guidance for 15–17% H2 growth and 60 new stores remains, with margin recovery expected as operations normalize.